Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Antituberculosis drugs)
4,660 results
  • One-pot green synthesis of chitosan biguanidine nanoparticles for targeting M. tuberculosis. [Journal Article]
    Int J Biol Macromol. 2023 Jan 23 [Online ahead of print]Abdallah HM, Abu Elella MH, Abdel-Aziz MM
  • Tuberculosis (TB) is considered as one of the most fatal infectious diseases nowadays. Several traditional anti-tuberculosis drugs like isoniazid have been largely applied; however, they are associated with toxicity and poor anti-TB treatment. So, the fabrication of new alternative anti-TB drugs containing natural biopolymers for TB treatment has attracted great attention in recent years because …
  • Biocompatible and biodegradable copper-protocatechuic metal-organic frameworks as rifampicin carrier. [Journal Article]
    Biomater Adv. 2022 Dec 22; 146:213269.Angkawijaya AE, Bundjaja V, … Ismadji S
  • Tuberculosis (TB) is a disease caused by the M. tuberculosis bacteria infection and is listed as one of the deadliest diseases to date. Despite the development of antituberculosis drugs, the need for long-term drug consumption and low patient commitment are obstacles to the success of TB treatment. A continuous drug delivery system that has a long-term effect is needed to reduce routine drug cons…
  • Essential oil of Gallesia integrifolia is active against mycobacteria. [Journal Article]
    Future Microbiol. 2023 Jan 20 [Online ahead of print]Montaholi DC, Valverde TL, … Cardoso RF
  • Background: There is critical need for new therapeutic options for treatment of diseases caused by mycobacteria. Materials & methods: Gallesia integrifolia essential oils (EOs) and crude extracts (CEs) were tested for their anti-Mycobacterium tuberculosis and anti-nontuberculous mycobacteria activity. Results: Minimum inhibitory concentration (MIC) of EOs ranged from 15.63 to 62.5 μg/ml against M…
  • Dual antituberculosis drugs-loaded gelatin hydrogel bioimplant for treating spinal tuberculosis. [Journal Article]
    Int J Pharm. 2023 Jan 13; 633:122609.Yahia S, Khalil IA, El-Sherbiny IM
  • Spinal tuberculosis (TB) represents around 1% of the recorded TB with a high mortality rate due to neurological complications and kyphosis. The current work aimed to develop a bioimplant scaffold to treat spinal TB disease. The scaffold is composed of a biocompatible semi-interpenetrating (semi-IPN) gelatin-based hydrogel incorporating mesoporous silica nanoparticles (MPS-NPs) loaded with rifampi…
  • Anti-tuberculosis drug development via targeting the cell envelope of Mycobacterium tuberculosis. [Review]
    Front Microbiol. 2022; 13:1056608.Xu X, Dong B, … Zeng J
  • Mycobacterium tuberculosis possesses a dynamic cell envelope, which consists of a peptidoglycan layer, a mycolic acid layer, and an arabinogalactan polysaccharide. This envelope possesses a highly complex and unique structure representing a barrier that protects and assists the growth of M. tuberculosis and allows its adaptation to the host. It regulates the immune response of the host cells, cau…
  • [Annual progress of chemotherapy of multidrug/rifampicin-resistant tuberculosis in 2022]. [Review]
    Zhonghua Jie He He Hu Xi Za Zhi. 2023 Jan 12; 46(1):62-66.Yu JJ, Tang SJ
  • At present, the number of cases with multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB) in China ranks fourth in the world, and the prevention and control situation is still serious. Chemotherapy, as the most important treatment for MDR/RR-TB, was studied and explored by domestic and foreign researchers in 2022. New chemotherapeutic drugs such as delpazolid, sutezolid, telacebec and independ…
  • Ardisia gigantifolia stapf (Primulaceae): A review of ethnobotany, phytochemistry, pharmacology, clinical application, and toxicity. [Review]
    J Ethnopharmacol. 2023 Apr 06; 305:116079.Tian-Liang , Xi-Gu-Ri-Gan , … Borjigidai A
  • CONCLUSIONS: To date, most bioactive compounds are identified from the rhizomes of A. gigantifolia, which pharmacological activity and clinical observational studies have validated the plant's traditional use as a treatment for rheumatoid arthritis. It would be helpful to verify the mechanism of some components in vivo, such as gigantifolinol. Moreover, the plant's triterpenoid saponins demonstrated valid anti-tumor effects, especially the AG4 and AG36 compounds, which were shown to have anti-breast cancer effects both in vitro and in vivo. Further research on these components, including molecular mechanisms and in vivo metabolic regulation, needs to be confirmed.
  • The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development. [Review]
    Mol Biomed. 2022 Dec 22; 3(1):48.Yan W, Zheng Y, … Cheng W
  • Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is a tenacious pathogen that has latently infected one third of the world's population. However, conventional TB treatment regimens are no longer sufficient to tackle the growing threat of drug resistance, stimulating the development of innovative anti-tuberculosis agents, with special emphasis on new protein targets. The…
New Search Next